Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Kaiser Permanente-Franklin — Denver, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
- Memorial Hospital North — Colorado Springs, Colorado
- UCHealth - Cherry Creek — Denver, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in Colorado: - Research Site — Aurora, Colorado
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Colorado: - Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- AdventHealth Porter — Denver, Colorado
- CommonSpirit Cancer Center Mercy — Durango, Colorado
- Mercy Medical Center — Durango, Colorado
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- UCHealth - Cherry Creek — Denver, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …
Sponsor: Pfizer
NCT ID: NCT07227415
Sites in Colorado: - Rocky Mountain Cancer Centers,LLP — Aurora, Colorado
- Clinical and Translational Research Center(CTRC) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado
- University of Colorado Hospital-Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
Phase 2 Recruiting NIH
This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04616560
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) — Denver, Colorado
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 2 Recruiting Academic/Other
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The pr…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05135975
Sites in Colorado: - Children's Hospital of Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 2 Recruiting Academic/Other
The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus…
Sponsor: University of Colorado, Denver
NCT ID: NCT05969496
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
- Hilands Ranch Hospital — Highlands Ranch, Colorado
- Lone Tree Medical Center — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very…
Sponsor: Jonsson Comprehensive Cancer Center
NCT ID: NCT06432036
Sites in Colorado: - University of Colorado Anschutz Medical Campus — Aurora, Colorado
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Colorado: - Exelixis Clinical Site #87 — Littleton, Colorado
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Colorado: - Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Colorado: - Sarah Cannon Research Institute at HealthOne — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalati…
Sponsor: HiberCell, Inc.
NCT ID: NCT06234605
Sites in Colorado: - University of Colorado Anschutz Medical Campus — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Colorado: - Sarah Cannon Research Institute - Denver DDU — Denver, Colorado
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Colorado: - Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
- The Medical Center of Aurora — Aurora, Colorado
- Rocky Mountain Regional VA Medical Center — Aurora, Colorado
- UCHealth University of Colorado Hospital — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Colorado: - Massive Bio SYNERGY-AI site — Aurora, Colorado
- Massive Bio SYNERGY-AI site — Denver, Colorado
- Massive Bio SYNERGY-AI site — Littleton, Colorado